StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Keros Therapeutics's price to book ratio was 0.7× on Nov 11, 2026, against 1.0× a year earlier. Over the last 5 years it ranged from 0.7× to 6.5×, with a median of 3.4×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.7×−0.5
2025Dec 31, 20251.2×+0.0
2024Dec 31, 20241.2×−2.8
2023Dec 29, 20234.0×−1.2
2022Dec 30, 20225.2×−1.1
2021Dec 31, 20216.3×−4.6
2020Dec 31, 202010.9×–

More Keros Therapeutics figures

See a number that looks wrong?